Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: J Neurochem. 2011 Oct 24;119(5):1119–1136. doi: 10.1111/j.1471-4159.2011.07497.x

Figure 6.

Figure 6

Effects of 27-OHC and concomitant treatment with LXR agonist GW3965 and LXR antagonist ECHS on α-synuclein expression in SH-SY 5Y neuroblastoma cells. (a) Representative Western blot (b) densitometric analysis, and (c) real time RT-PCR analysis demonstrate that 27-OHC significantly increases α-synuclein protein and mRNA levels. Treatment with the LXR agonist GW3965 also significantly increases α-synuclein protein and mRNA levels. Co-treatment with 27-OHC and the LXR agonist GW3965 accentuates the increase induced by 27-OHC on α-synuclein protein levels, but not mRNA levels. Treatment with the LXR antagonist ECHS produces no effect on the levels of α-synuclein protein and mRNA. However, the LXR antagonist ECHS significantly reverses the 27-OHC-induced increase in α-synuclein protein and mRNA levels. Data is expressed as Mean ± S.E.M and includes determinations made in four separate cell culture experiments (n=4). *p<0.05, **p<0.01 and ***p<0.001 versus control, †† p<0.01 and ††† p<0.001 versus 27-OHC; ΔΔ p<0.01 versus ECHS.